[HTML][HTML] Glioblastoma chemoresistance: the double play by microenvironment and blood-brain barrier

M Da Ros, V De Gregorio, AL Iorio, L Giunti… - International journal of …, 2018 - mdpi.com
M Da Ros, V De Gregorio, AL Iorio, L Giunti, M Guidi, M De Martino, L Genitori, I Sardi
International journal of molecular sciences, 2018mdpi.com
For glioblastoma, the tumor microenvironment (TME) is pivotal to support tumor progression
and therapeutic resistance. TME consists of several types of stromal, endothelial and
immune cells, which are recruited by cancer stem cells (CSCs) to influence CSC phenotype
and behavior. TME also promotes the establishment of specific conditions such as hypoxia
and acidosis, which play a critical role in glioblastoma chemoresistance, interfering with
angiogenesis, apoptosis, DNA repair, oxidative stress, immune escape, expression and …
For glioblastoma, the tumor microenvironment (TME) is pivotal to support tumor progression and therapeutic resistance. TME consists of several types of stromal, endothelial and immune cells, which are recruited by cancer stem cells (CSCs) to influence CSC phenotype and behavior. TME also promotes the establishment of specific conditions such as hypoxia and acidosis, which play a critical role in glioblastoma chemoresistance, interfering with angiogenesis, apoptosis, DNA repair, oxidative stress, immune escape, expression and activity of multi-drug resistance (MDR)-related genes. Finally, the blood brain barrier (BBB), which insulates the brain microenvironment from the blood, is strongly linked to the drug-resistant phenotype of glioblastoma, being a major physical and physiological hurdle for the delivery of chemotherapy agents into the brain. Here, we review the features of the glioblastoma microenvironment, focusing on their involvement in the phenomenon of chemoresistance; we also summarize recent advances in generating systems to modulate or bypass the BBB for drug delivery into the brain. Genetic aspects associated with glioblastoma chemoresistance and current immune-based strategies, such as checkpoint inhibitor therapy, are described too.
MDPI